Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Researchers identify biomarker to predict tivozanib drug resistance

Researchers believe there may be a way to predict, based on individual tumors, those patients that are more likely to respond to the investigational new drug tivozanib.

29 Sep 2010

Loss of INPP5A gene can predict cutaneous squamous cell carcinoma progression

The loss of a gene known as INPP5A could predict the onset, and track the progression, of an aggressive type of skin cancer, according to a study published today by the Mayo Clinic, Arizona Cancer Center, and the Translational Genomics Research Institute (TGen).

29 Sep 2010

Researchers discover new diagnostic test for prostate cancer

Researchers in England say they have discovered a set of biomarkers that can distinguish prostate cancer from benign prostate disease and healthy tissue with 90 percent accuracy.

From Oxford Gene Technology 29 Sep 2010

Triple-negative breast cancer patients may have unique biomarker to receive targeted therapy: Research

Patients with triple negative breast cancer, one of the hardest subtypes to treat, may have a unique biomarker that would enable them to receive more targeted therapy, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

29 Sep 2010

NCI awards A&G $1.2M Phase II SBIR grant for development of breast cancer drug candidate

A&G Pharmaceutical announced today that it has received $1.2 million in Phase II Small Business Innovation Research (SBIR) funding from the National Cancer Institute (NCI) for the program, "Novel Targeted Therapy for Breast Cancer," focused on the development of a neutralizing therapeutic antibody against a novel cancer-associated protein, GP88.

29 Sep 2010

Family members, friends are more sensitive to early signs of Alzheimer's dementia: Researchers

Family members and close friends are more sensitive to early signs of Alzheimer's dementia than traditional screening tests, according to researchers at Washington University School of Medicine in St. Louis.

28 Sep 2010

NPL, Orla receives fund to improve detection methods for TB

Two UK companies have been awarded joint funding for a research project that could see significant advances in the quest to aid detection and eradication of Tuberculosis (TB), across the world.

28 Sep 2010

Michael J. Fox Foundation launches PPMI clinical study to identify Parkinson's disease biomarkers

The Michael J. Fox Foundation has launched the Parkinson's Progression Markers Initiative (PPMI), the first ever large scale clinical study exclusively focused on identifying and validating Parkinson's disease biomarkers.

28 Sep 2010

Genomics obtains worldwide rights to The Garvan Institute of Medical Research's methylation DNA biomarkers

Clinical Genomics Pty. Ltd (Sydney, Australia) and The Garvan Institute of Medical Research (Sydney, Australia) today announced that they have entered into a license agreement in relation to novel biomarkers discovered by scientists at the Garvan Institute. Under the terms of the agreement, Clinical Genomics obtains worldwide exclusive rights to the Garvan's proprietary cancer associated methylation DNA biomarkers for the diagnosis and or treatment of colorectal cancer.

28 Sep 2010

BMC physicians to lead international research collaboration to curb infectious diseases

Boston Medical Center (BMC) has been chosen to lead an investigation aimed at developing novel approaches to prevent tuberculosis (TB). Jerrold J. Ellner, MD, chief of the section of infectious diseases at BMC and professor of medicine at the Boston University School of Medicine (BUSM), a renowned expert in the field, will serve as principal investigator (PI) on the five-year, $3 million grant funded by the National Institutes of Health (NIH).

27 Sep 2010

Clinical Data announces Stedivaze agonist data at ASNC2010 meeting

Clinical Data, Inc., today presented data from Phase I studies of Stedivaze (apadenoson), which demonstrated overall safety and tolerability in patients with asthma and chronic obstructive pulmonary disease (COPD).

27 Sep 2010

Enobia announces positive results from ENB-0040 Phase II juvenile clinical trial for hypophosphatasia

Enobia Pharma today announced positive results for its Phase II juvenile clinical trial of ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy intended for the treatment of hypophosphatasia (HPP). Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages.

24 Sep 2010

CIC proposes criteria to improve endpoints for cancer immunotherapy trials

The Cancer Research Institute (CRI) Cancer Immunotherapy Consortium (CIC), the leading global initiative in advancing the emerging field of immuno-oncology, has proposed criteria for improved endpoints for cancer immunotherapy trials, which were published online on September 8 in the Journal of the National Cancer Institute.

24 Sep 2010

Boehringer Ingelheim, Eurofins Medigenomix partner in DNA banking and pharmacogenetics, pharmacogenomics

Boehringer Ingelheim Pharma GmbH & Co. KG, an international research-driven pharma company, and Eurofins Medigenomix GmbH, a competence center for genetic analyses of the Eurofins Scientific Group, concluded a long-term service agreement in the area of DNA banking, as well as a master service agreement for pharmacogenetic and pharmacogenomic services. For DNA banking Eurofins Medigenomix is supporting operations of Boehringer Ingelheim's central DNA bank at Biberach an der Riss.

23 Sep 2010

Metabolon publishes biomarker validation study results for periodontal diseases

Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announces the publication of "Assessment of Dentifrice on Periodontal Disease Biomarkers in Gingival Crevicular Fluid", in the Journal of Periodontology.

23 Sep 2010

Agilent, ISB and ETH Zurich enter second phase of mapping complete human proteome

Ninth Annual World Conference of the Human Proteome Organization -- Agilent Technologies Inc. (NYSE:A) today announced that its collaboration with the Institute for Systems Biology (ISB) and the Swiss Federal Institute of Technology (ETH Zurich) for the mapping of the complete human proteome by mass spectrometry is entering its second phase.

22 Sep 2010

AACR to host fourth International Conference on Molecular Diagnostics

The American Association for Cancer Research will host its Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development from Sept. 27-30, 2010, at the Sheraton Denver Downtown in Denver, Colo.

22 Sep 2010

Study demonstrates why targeted therapies do not work in majority of people

In order for targeted therapies against cancer to be effective, scientists need to understand upfront what related proteins in a signaling "network" makes a cancer cell resistant to a drug and selectively target them as well, say researchers at Georgetown Lombardi Comprehensive Cancer Center and Fox Chase Cancer Center.

22 Sep 2010

Aethlon Medical reestablishes efforts to advance Aethlon Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has reestablished efforts to advance the Aethlon Hemopurifier within U.S. Government programs that support the development and purchase of treatment countermeasures against bioterror threats.

21 Sep 2010

Health Canada issues license for IgX PLEX Celiac test kit

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based biomarker testing, announced today that Health Canada has issued a medical device license for its automated IgX PLEX Celiac(TM) microarray test kit that runs on the Company's automated SQiDworks(TM) platform. The license allows the Company to market and sell the IgX PLEX Celiac product in Canada.

21 Sep 2010

Biomarker News and Research

Further Reading

Researchers identify biomarker to predict tivozanib drug resistance

Loss of INPP5A gene can predict cutaneous squamous cell carcinoma progression

Researchers discover new diagnostic test for prostate cancer

Triple-negative breast cancer patients may have unique biomarker to receive targeted therapy: Research

NCI awards A&G $1.2M Phase II SBIR grant for development of breast cancer drug candidate

Family members, friends are more sensitive to early signs of Alzheimer's dementia: Researchers

NPL, Orla receives fund to improve detection methods for TB

Michael J. Fox Foundation launches PPMI clinical study to identify Parkinson's disease biomarkers

Genomics obtains worldwide rights to The Garvan Institute of Medical Research's methylation DNA biomarkers

BMC physicians to lead international research collaboration to curb infectious diseases

Clinical Data announces Stedivaze agonist data at ASNC2010 meeting

Enobia announces positive results from ENB-0040 Phase II juvenile clinical trial for hypophosphatasia

CIC proposes criteria to improve endpoints for cancer immunotherapy trials

Boehringer Ingelheim, Eurofins Medigenomix partner in DNA banking and pharmacogenetics, pharmacogenomics

Metabolon publishes biomarker validation study results for periodontal diseases

Agilent, ISB and ETH Zurich enter second phase of mapping complete human proteome

AACR to host fourth International Conference on Molecular Diagnostics

Study demonstrates why targeted therapies do not work in majority of people

Aethlon Medical reestablishes efforts to advance Aethlon Hemopurifier

Health Canada issues license for IgX PLEX Celiac test kit

Event guide: 16th Clinical Biomarkers & CDx Summit Europe eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo